HHS, HRSA Tell Judge They Don’t Know When They’ll Replace 340B Dispute Resolution Process

340B administrative dispute resolution
HHS and HRSA recently told a federal district court they “are unable to predict” when they will finally replace HRSA’s 340B administrative dispute resolution proces.

The U.S. Department of Health and Human Services and the Health Resources and Services Administration “are unable to predict” when they will finally replace HRSA’s 340B administrative dispute resolution process, the government said in a recent legal filing.

The government

Read More »

HRSA Posts Four Manufacturer Notices to 340B Entities

Humalog
Lilly is providing refunds for 340B overcharges during Q1 2020 on Humalog and Trulicity.

The U.S. Health Resources and Services Administration yesterday posted notices of refunds for 340B overcharges from drug manufacturers Lilly, Novo Nordisk, and Neurocrine and a notice from Amneal about product NDC changes.

Lilly

Lilly’s May 30 notice covers purchases

Read More »

HRSA Allows Immediate 340B Enrollment in Guam Due to Typhoon

Guam typhoon Mawar
Destruction in Tamuning, Guam, caused by super typhoon Mawar, which made landfall on May 24 as a Category 4-equivalent storm.

Health care providers in Guam eligible to participate in the 340B program may do so immediately, rather than having to wait for the next normal quarterly registration period July 1-15, the U.S. Health Resources and Services Administration said yesterday.

Secretary

Read More »

ASAP 340B and AHA Outreach Documents Are Polar Opposites on 340B DSH Hospitals

ASAP 340B
A new ASAP 340B document describes how its position on the 340B patient definition would play out under six hypothetical scenarios.

ASAP 340B, the group that drug manufacturers and community health centers formed to advance a joint 340B reform agenda, recently released a two-page explainer on how their plan would change the 340B patient definition. Under it, fewer drugs prescribed at

Read More »

Merck to Pay Refunds for 340B Overcharges in Q1 and Q2 2020

Cubicin
Merck is providing refunds for 340B overcharges on NDCs of its antibiotic Cubicin and other drugs during the first two quarters of 2020.

Drug manufacturer Merck is paying refunds for overcharges on 340B drugs purchased during the first two quarters of 2020.

Merck recently asked the U.S. Health Resources and Services Administration to post notices about its 340B ceiling price recalculations on the

Read More »

News Alert

Organon Is the 22nd Drug Maker to Impose Limits on 340B Contract Pharmacy

Organon
Organon today became the 22nd drug maker to announce conditions on 340B pricing involving drug shipments to contract pharmacies. They apply to hospitals only, grantee covered entities are exempt.

Drug manufacturer Organon, the Merck spinoff with a focus on women’s health, today became the 22nd drug maker to impose conditions on 340B pricing involving delivery to contract pharmacies.

Covered entities began receiving an email from Organon around 3:00 p.m.

Read More »

News Alert

Novo Nordisk Tightens its 340B Contract Pharmacy Policy Today, Others Possible

Novo Nordisk
Novo Nordisk today stiffened its 340B contract pharmacy conditions, which affect hospital covered entities only.

Drug manufacturer Novo Nordisk today announced that effective July 1 it will stop letting hospitals place bill to / ship to orders of 340B-purchased drugs to an unlimited number of contract pharmacies in exchange for related claims data.

It will,

Read More »

CMS Is a Step Closer to Saying How It Will Fix Medicare Drug Payment Cuts for 340B Hospitals

OMB
CMS sent its proposed remedy for illegal Medicare Part B drug payment cuts for 340B hospitals to the White House for clearance to be released.

The U.S. Centers for Medicare & Medicaid Services has sent its proposed remedy for almost five years of illegal Medicare Part B drug payments cuts for 340B hospitals to the White House for clearance to be published in the Federal

Read More »

CMS Proposes Rules That Addresses 340B Duplicate Discounts in Medicaid Managed Care

CMS
CMS proposes adding information to Medicaid managed care beneficiaries' insurance cards to facilitate 340B duplicate discount prevention.

The U.S. Centers for Medicare & Medicaid Services wants to make Medicaid managed care organizations use Medicaid-specific codes and group numbers on beneficiary insurance cards to help states, MCOs, and 340B covered entities avoid invoicing manufacturers for prohibited duplicate 340B

Read More »

340B Report Publisher and CEO: Is a Contract Pharmacy Breakthrough at Hand?

Breakthrough
Hospital groups' decision to back federal 340B contract pharmacy legislation could be a long-awaited breakthrough, 340B Report Publisher and CEO Ted Slafsky says.

Hospital groups’ decision to support letting Congress end the 340B contract pharmacy standoff could be the breakthrough the field has been waiting for, 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Verity Solutions.

“National hospital

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live